Ikarian Capital, LLC Inhibrx, Inc. Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.52 - $25.26 $924,164 - $2.74 Million	-108,470 Reduced 68.72%	49,372 $561,000
Q1 2022 May 13, 2022	BUY	$19.89 - $43.18 $158,960 - $345,094	7,992 Added 5.33%	157,842 $3.52 Million
Q4 2021 Feb 14, 2022	SELL	$26.75 - $46.02 $3.75 Million - $6.44 Million	-140,000 Reduced 48.3%	149,850 $6.54 Million
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $7.1 Million - $10.7 Million	281,774 Added 3489.03%	289,850 $9.65 Million
Q4 2020 Feb 12, 2021	BUY	$15.96 - $50.0 $128,892 - $403,800	8,076 New	8,076 $266,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $550M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.